--First data disclosure from Ribometrix’s RNA-targeting drug discovery platform identifies small molecules targeting c-MYC, a validated but historically undruggable cancer driver -- --Data shows ...

The c-Myc oncoprotein is frequently overexpressed in human cancers and is essential for cancer cell proliferation. The dysregulation of ubiquitin-proteasome-mediated degradation is one of the ...

UTR Therapeutics plans to initiate a Phase 1 trial of UTRxM1-18 in patients with advanced c-MYC–driven tumors pending regulatory approvals. The company is also exploring translational and commercial ...

Unless otherwise listed, all solvents and reagents were purchased from Aldrich Chemical Co. (MO, USA) and used as received. Anhydrous chloroform and methanol were purchased from Aldrich Chemical Co.

Race Oncology has achieved a breakthrough with its lead drug candidate RC220, identifying for the first time the primary ...

Breast cancer is the most frequent malignancy among women worldwide, and all subtypes of breast cancer involve upregulation of the c-Myc gene, making it a compelling therapeutic target. G-rich regions ...

The Innovation Center of NanoMedicine (Director General: Prof. Kazunori Kataoka, Location: Kawasaki in Japan, Abbreviation: iCONM) reported in ACS Nano (Impact Factor: 14.588 in 2019) together with ...

Suzhou Kintor Pharmaceuticals Inc. has identified proteolysis targeting chimera (PROTAC) compounds comprising cereblon (CRBN) binding moiety covalently linked to Myc proto-oncogene protein (c-Myc), ...

Myc dysregulation in activated macrophages impairs antioxidant defenses, locking them in a vicious cycle that amplifies type I interferon signaling, driving hyperinflammation and immunosuppression.

Researchers from Tulane University have uncovered a previously unknown molecular pathway that could be key to halting lung cancer. Their study in mice demonstrates that a known tumor suppressor ...